版本:
中国

BRIEF-Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation

Sept 30 Enanta Pharmaceuticals Inc

* Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation

* According to FDA,BTD is intended to expedite development,review of an investigational therapy for serious condition Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐